AEGON Asset Management (UK)’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.3M | Sell |
192,146
-30,800
| -14% | -$4.06M | 0.26% | 81 |
|
|
2026
Q1 | $31.1M | Hold |
222,946
| – | – | 0.41% | 69 |
|
|
2025
Q4 | $27.4M | Sell |
222,946
-20,635
| -8% | -$2.51M | 0.33% | 82 |
|
|
2025
Q3 | $27M | Sell |
243,581
-9,648
| -4% | -$1.1M | 0.32% | 80 |
|
|
2025
Q2 | $28.1M | Sell |
253,229
-32,588
| -11% | -$3.47M | 0.36% | 71 |
|
|
2025
Q1 | $32M | Buy |
285,817
+18,343
| +7% | +$1.89M | 0.47% | 54 |
|
|
2024
Q4 | $24.7M | Buy |
267,474
+6,968
| +3% | +$627K | 0.33% | 78 |
|
|
2024
Q3 | $21.8M | Sell |
260,506
-4,954
| -2% | -$378K | 0.3% | 87 |
|
|
2024
Q2 | $18.2M | Sell |
265,460
-23,811
| -8% | -$1.59M | 0.26% | 90 |
|
|
2024
Q1 | $21.2M | Sell |
289,271
-500,395
| -63% | -$38.5M | 0.32% | 64 |
|
|
2023
Q4 | $64M | Buy |
+789,666
| New | +$61.4M | 1.02% | 26 |
|
|
2023
Q2 | $87.5M | Sell |
1,136,909
-8,983
| -0.8% | -$716K | 1.42% | 12 |
|
|
2023
Q1 | $95M | Sell |
1,145,892
-95,661
| -8% | -$7.92M | 1.66% | 11 |
|
|
2022
Q4 | $107M | Sell |
1,241,553
-52,473
| -4% | -$4.16M | 1.93% | 13 |
|
|
2022
Q3 | $79.9M | Sell |
1,294,026
-3,200
| -0.2% | -$202K | 1.62% | 15 |
|
|
2022
Q2 | $80.2M | Buy |
1,297,226
+23,585
| +2% | +$1.46M | 1.51% | 17 |
|
|
2022
Q1 | $75.7M | Buy |
1,273,641
+264,227
| +26% | +$16.9M | 1.12% | 19 |
|
|
2021
Q4 | $73.3M | Sell |
1,009,414
-4,824
| -0.5% | -$332K | 0.94% | 29 |
|
|
2021
Q3 | $70.8M | Sell |
1,014,238
-8,917
| -0.9% | -$626K | 1.01% | 28 |
|
|
2021
Q2 | $70.4M | Sell |
1,023,155
-77,532
| -7% | -$5.18M | 1% | 28 |
|
|
2021
Q1 | $71.1M | Sell |
1,100,687
-204,030
| -16% | -$13.2M | 1.06% | 28 |
|
|
2020
Q4 | $75.9M | Buy |
1,304,717
+822,466
| +171% | +$49.6M | 1.11% | 26 |
|
|
2020
Q3 | $30.5M | Buy |
482,251
+23,431
| +5% | +$1.62M | 0.62% | 55 |
|
|
2020
Q2 | $35.3M | Buy |
+458,820
| New | +$35.2M | 0.79% | 49 |
|
|
2018
Q2 | – | Sell |
-432,423
| Closed | -$32.6M | – | 176 |
|
|
2018
Q1 | $32.6M | Sell |
432,423
-17,330
| -4% | -$1.38M | 0.84% | 46 |
|
|
2017
Q4 | $32.2M | Hold |
449,753
| – | – | 0.82% | 48 |
|
|
2017
Q3 | $36.4M | Hold |
449,753
| – | – | 1% | 36 |
|
|
2017
Q2 | $31.8M | Sell |
449,753
-11,136
| -2% | -$741K | 0.9% | 40 |
|
|
2017
Q1 | $31.3M | Sell |
460,889
-1,165
| -0.3% | -$81.9K | 0.84% | 46 |
|
|
2016
Q4 | $33.1M | Buy |
462,054
+134,546
| +41% | +$10M | 0.94% | 42 |
|
|
2016
Q3 | $25.9M | Sell |
327,508
-8,288
| -2% | -$673K | 0.73% | 42 |
|
|
2016
Q2 | $28M | Buy |
335,796
+9,407
| +3% | +$835K | 0.8% | 41 |
|
|
2016
Q1 | $30M | Sell |
326,389
-12,579
| -4% | -$1.13M | 0.9% | 39 |
|
|
2015
Q4 | $34.3M | Sell |
338,968
-190,504
| -36% | -$19.8M | 1% | 35 |
|
|
2015
Q3 | $51.9M | Sell |
529,472
-1,194
| -0.2% | -$133K | 1.57% | 22 |
|
|
2015
Q2 | $62.1M | Sell |
530,666
-20,575
| -4% | -$2.25M | 1.72% | 19 |
|
|
2015
Q1 | $54.1M | Buy |
551,241
+460,356
| +507% | +$46.7M | 1.42% | 28 |
|
|
2014
Q4 | $8.57M | Sell |
90,885
-12,949
| -12% | -$1.34M | 0.95% | 29 |
|
|
2014
Q3 | $11.1M | Sell |
103,834
-13,473
| -11% | -$1.32M | 1.25% | 24 |
|
|
2014
Q2 | $9.73M | Buy |
117,307
+36,635
| +45% | +$2.85M | 1.12% | 24 |
|
|
2014
Q1 | $5.71M | Buy |
+80,672
| New | +$6.33M | 0.66% | 39 |
|
Other funds holding GILD
AEGON Asset Management (UK)'s GILD Position: Q2 2026 in Review
AEGON Asset Management (UK) reduced its Gilead Sciences (GILD) stake by 14% in Q2 2026, selling an estimated $4.06M and leaving 192,146 shares worth $24.3M. The position accounts for 0.26% of the portfolio, ranked #81.
AEGON Asset Management (UK) first reported a position in GILD in Q1 2014 and has held it in 41 quarters since. The position peaked at $107M in Q4 2022. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- AEGON Asset Management (UK) held 192,146 shares of Gilead Sciences worth $24.3M as of Q2 2026.
- AEGON Asset Management (UK) sold 30,800 Gilead Sciences shares in Q2 2026, an estimated $4.06M.
- Gilead Sciences made up 0.26% of AEGON Asset Management (UK)'s portfolio in Q2 2026, its #81 holding.
- AEGON Asset Management (UK) first reported a position in Gilead Sciences in Q1 2014 and has held it in 41 quarters since.
- AEGON Asset Management (UK)'s Gilead Sciences position peaked at $107M in Q4 2022.
- 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on AEGON Asset Management (UK)'s 13F filing for Q2 2026, filed 13 Jul 2026.